Skyrizi Injection, Solution
NDC Package 0074-4059-71

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Other Packages
    3. Frequently Asked Questions

Package Information

Skyrizi (risankizumab-rzaa) injection is a medication used to treat plaque psoriasis. This formulation utilizes a injection, solution delivery system. Marketed by Abbvie Inc., this product is identified by NDC 0074-4059 and is authorized under FDA application BLA761105.

Identification & Billing

NDC Package Code
0074-4059-71
Package Description
1 SYRINGE, GLASS in 1 CARTON / .37 mL in 1 SYRINGE, GLASS
Product Code
0074-4059
11-Digit Billing Format
00074405971

Clinical Specifications

Proprietary Name
Skyrizi
Non-Proprietary Name
Risankizumab-rzaa
Substance Name
Risankizumab
Dosage Form
Injection, Solution - A liquid preparation containing one or more drug substances dissolved in a suitable solvent or mixture of mutually miscible solvents that is suitable for injection.
Administration Route
Subcutaneous - Administration beneath the skin; hypodermic. Synonymous with the term SUBDERMAL.
Active Ingredient(s)
RISANKIZUMAB 55 mg/.37mL
Pharmacologic Class
Usage Information
This medication is used to treat plaque psoriasis. Risankizumab-rzaa belongs to a class of drugs known as monoclonal antibodies. It works by blocking a certain natural protein in your body (interleukin-23) that may cause inflammation and swelling.

Regulatory & Marketing

Labeler Name
Abbvie Inc.
Product Type
Human Prescription Drug
FDA Application #
BLA761105
Marketing Category
BLA - A product marketed under an approved Biologic License Application.
Start Marketing Date
06-12-2026
Listing Expiration
12-31-2027
Exclude Flag
N
Sample Package
Yes

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Other Available Packages

The following commercial packages are registered under the same Product NDC (0074-4059). Click a package code to view its specific billing and regulatory data.

0074-4059-01
1 SYRINGE, GLASS in 1 CARTON / .37 mL in 1 SYRINGE, GLASS

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 0074-4059-71 identifies a specific commercial package of 1 syringe, glass in 1 carton / .37 ml in 1 syringe, glass of Skyrizi, a human prescription drug labeled by Abbvie Inc.. This injection, solution is formulated for subcutaneous use and contains risankizumab as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Abbvie Inc. on June 12, 2026. The current certification is valid through December 31, 2027.

What are the primary indications for this medication?

This medication is used to treat plaque psoriasis. Risankizumab-rzaa belongs to a class of drugs known as monoclonal antibodies. It works by blocking a certain natural protein in your body (interleukin-23) that may cause inflammation and swelling.

How is this Abbvie Inc. product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 00074405971. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (4-4-2)
0074-4059-71
11-Digit CMS (5-4-2)
00074-4059-71

Note: The zero is added to the Labeler segment to maintain the 5-4-2 structure.